Clinical trial · no report yet · Phase 3
AndroMETa-CRC
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- NCT07525206 ↗
- Recruiting
- AbbVie
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Plus Bevacizumab to LONSURF (Trifluridine and Tipiracil) Plus Bevacizumab in Subjects With Refractory Metastatic Colorectal Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- Telisotuzumab adizutecan; Bevacizumab; Trifluridine/Tipiracil
- Arms
- Ph 3: Telisotuzumab Adizutecan + Bevacizumab · Experimental
- Ph 3: SOC Trifluridine and Tipiracil + Bevacizumab · Experimental
- Enrollment
- 990 (estimated)
- Primary outcomes
- Phase 3: Objective Response (OR) as assessed by Blinded Independent Central Review (BICR)
- Phase 3: Overall Survival (OS)
- Sponsor
- AbbVie
- Start
- May 22, 2026
- Primary completion
- May 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07525206 · updated Oct 19, 2026